Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China

Combines Blueprint Medicines' Lead Clinical Programs with CStone Pharmaceutical's Regional Expertise Expands BLU-554 Development Program in Hepatocellular Carcinoma with Plans to Bring Ongoing Monotherapy Trial to China and Initiate Proof-of-Concept Com... Biopharmaceuticals, Oncology, Licensing Blueprint Medicines, CStone Pharmaceuticals, Avapritinib
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news